Holding

dentalcorp Announces Extension of Maturity of Credit Facility

Retrieved on: 
Tuesday, January 23, 2024
Biotechnology, Finance, Health, Professional Services, Dental, Holding, TD Securities, Bank, TSX, Bank of America, RBC Capital Markets, Growth

dentalcorp Holdings Ltd. (“dentalcorp” or the “Company”) (TSX: DNTL), Canada’s leading network of dental practices, today announced an extension to its existing syndicated senior secured credit facility with a consortium of banks, led by CIBC Capital Markets and TD Securities.

Key Points: 
  • dentalcorp Holdings Ltd. (“dentalcorp” or the “Company”) (TSX: DNTL), Canada’s leading network of dental practices, today announced an extension to its existing syndicated senior secured credit facility with a consortium of banks, led by CIBC Capital Markets and TD Securities.
  • The maturity date of the credit facility will be extended to January 18, 2028, from its original May 27, 2026 date.
  • Concurrently, dentalcorp reduced the facility amount from $1.75 billion to $1.4 billion.
  • In addition, dentalcorp has fully hedged the previously unhedged portion of its credit facility.

WNS Announces Fiscal 2024 Third Quarter Earnings, Revises Full Year Guidance

Retrieved on: 
Thursday, January 18, 2024
Data Management, Banking, Accounting, Technology, Professional Services, Other Technology, Software, Other Professional Services, Internet, Finance, Electronic Design Automation, Bank statement, INR, BPM, ANI, Health, AI, Public expenditure, GAAP, ADS, Generative, Investment, Acquisition, USD, Webcast, Business process management, Automation, Exercise, Holding, Growth, Security (finance)

WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today announced results for the fiscal 2024 third quarter ended December 31, 2023.

Key Points: 
  • WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today announced results for the fiscal 2024 third quarter ended December 31, 2023.
  • Profit in the fiscal third quarter was $39.6 million, as compared to $34.7 million in Q3 of last year and $57.8 million in the previous quarter.
  • Guidance assumes an average USD to INR exchange rate of 83.3 for the remainder of fiscal 2024.
  • WNS will host a conference call on January 18, 2024, at 8:00 am (Eastern) to discuss the company's quarterly results.

TC BioPharm to Present at the Sequire Investor Summit

Retrieved on: 
Thursday, January 18, 2024
PLC, Condado Vanderbilt Hotel, Cancer, Holding

EDINBURGH, Scotland, Jan. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

Key Points: 
  • EDINBURGH, Scotland, Jan. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
  • TC BioPharm CEO, Bryan Kobel, will conduct in person one-on-one meetings throughout the conference and deliver the Company's presentation to registered participants as shown below.
  • Location: Condado Vanderbilt Hotel in San Juan, Puerto Rico
    For more information about the Sequire Investor Summit, including registration details or to schedule a 1x1 meeting, please visit the official event website at https://puertorico.srax.com/ or contact [email protected]

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Retrieved on: 
Wednesday, January 10, 2024
BH3, Patient, Associate, CLL, RNA, RNA interference, Cancer, Safety, University, AML, New York Medical College, Holding

High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed, aggressive non-Hodgkin’s lymphoma.

Key Points: 
  • High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed, aggressive non-Hodgkin’s lymphoma.
  • In the Phase 1 trial, refractory/relapsed CLL patients, including those who have failed or relapsed from venetoclax-based frontline therapy, as well as refractory/relapsed lymphoma patients, will be treated with BP1002.
  • As a result, Bio-Path believes that BP1002 could provide an alternative treatment for venetoclax refractory/relapsed CLL patients.
  • The primary objective of the study is to evaluate the safety and tolerability of escalating doses of BP1002.

Rival Names David McDonald Vice President of Mergers & Acquisitions

Retrieved on: 
Tuesday, January 9, 2024
M&A, Holding, Network equipment provider

FORT WAYNE, Ind., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Rival Holdings has named David McDonald vice president of mergers and acquisitions.

Key Points: 
  • FORT WAYNE, Ind., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Rival Holdings has named David McDonald vice president of mergers and acquisitions.
  • “David is the right leader to advance our mission of transforming the industry,” said Brad Crawford, CEO of Rival.
  • In his role at Rival, McDonald will lead M&A activities, driving growth and expansion through strategic acquisitions, joint ventures, partnerships, greenfielding, and divestitures.
  • “I am honored to be a part of the talented and forward-thinking Rival team,” said McDonald.

AtlasClear Announces the Extension of Business Combination Agreement with Quantum FinTech Acquisition Corporation and the Restructuring of its Proposed Acquisition of Wilson-Davis & Co, Inc.

Retrieved on: 
Wednesday, January 10, 2024
Banking, Fintech, Professional Services, Finance, Quantum, Acquisition, Holding, Financial services

AtlasClear, Inc. (“AtlasClear”) announced today the extension of the agreement to complete its previously announced business combination with Quantum FinTech Acquisition Corporation (“Quantum”) (NYSE: QFTA), a publicly-traded special purpose acquisition company, which was approved by Quantum’s stockholders on November 3, 2023.

Key Points: 
  • AtlasClear, Inc. (“AtlasClear”) announced today the extension of the agreement to complete its previously announced business combination with Quantum FinTech Acquisition Corporation (“Quantum”) (NYSE: QFTA), a publicly-traded special purpose acquisition company, which was approved by Quantum’s stockholders on November 3, 2023.
  • Additionally, AtlasClear restructured its proposed acquisition of Wilson-Davis & Co., Inc. (“Wilson-Davis”), to facilitate the closing of that transaction.
  • In November 2022, Quantum entered into a definitive business combination agreement that is expected to result in Atlas FinTech Holdings Corp. transferring its trading technology assets to AtlasClear and the acquisition by AtlasClear of Wilson-Davis.
  • AtlasClear has also entered into a definitive agreement to acquire Commercial Bancorp of Wyoming, a federal reserve member (“Commercial Bancorp”), following consummation of the business combination.

Arm Announces Earnings Release Date for Third Quarter Fiscal Year Ended 2024

Retrieved on: 
Tuesday, January 9, 2024
Data Management, Technology, Professional Services, Semiconductor, Apps, Applications, Software, Networks, Internet, Mobile, Wireless, Hardware, Finance, ARM, Arm, Holding

Arm Holdings plc (Nasdaq: ARM, “Arm”) today announced it will report financial results for the third quarter of fiscal year 2024 on Wednesday, February 7, 2024, after market close.

Key Points: 
  • Arm Holdings plc (Nasdaq: ARM, “Arm”) today announced it will report financial results for the third quarter of fiscal year 2024 on Wednesday, February 7, 2024, after market close.
  • The company will host a conference call via audio webcast at 14:00 Pacific Time (17:00 Eastern Time / 22:00 Greenwich Mean Time) to review its financial results and business outlook.
  • Financial and other statistical information to be discussed on this conference call.
  • The live audio webcast will be available here and a replay of the conference call can be accessed on http://investors.arm.com/ shortly afterwards.

Luxfer Declares Quarterly Dividend

Retrieved on: 
Tuesday, January 9, 2024
Engineering, Other Manufacturing, Manufacturing, Holding, Holding company

Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced that its Board of Directors declared a quarterly dividend of 13 cents per ordinary share.

Key Points: 
  • Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced that its Board of Directors declared a quarterly dividend of 13 cents per ordinary share.
  • The dividend will be payable on February 07, 2024 to shareholders of record as of the close of business on January 19, 2024.

WNS to Release Fiscal 2024 Third Quarter Financial and Operating Results on January 18, 2024

Retrieved on: 
Wednesday, January 3, 2024
Professional Services, Data Management, Technology, Insurance, Software, Finance, Fintech, Business process management, Webcast, Holding, BPM

WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today announced it will release its fiscal 2024 third quarter financial and operating results at approximately 6:00 a.m. Eastern on Thursday, January 18, 2024.

Key Points: 
  • WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) solutions, today announced it will release its fiscal 2024 third quarter financial and operating results at approximately 6:00 a.m. Eastern on Thursday, January 18, 2024.
  • Following the release, WNS management will host a call on January 18, 2024 at 8:00 a.m. Eastern.
  • Chief Executive Officer, Keshav Murugesh, and Chief Financial Officer, Sanjay Puria will review the results of the fiscal 2024 third quarter ended December 31, 2023 on the teleconference.
  • To access the call in “listen-only” mode, please join live via the company’s investor relations website at ir.wns.com .

WNS Recognized as a ‘Leader’ in Insurance by ISG

Retrieved on: 
Tuesday, January 2, 2024
Professional Services, Data Management, Technology, Insurance, Software, Finance, Fintech, P&C, As a service, BPM, UAP, Business process management, General insurance, Holding, Property, ISG, BPO

In North America, WNS was named a ‘Leader’ in Life and Retirement (L&R) Insurance BPO, Property and Casualty (P&C) Insurance BPO, and Life & Retirement Insurance TPA.

Key Points: 
  • In North America, WNS was named a ‘Leader’ in Life and Retirement (L&R) Insurance BPO, Property and Casualty (P&C) Insurance BPO, and Life & Retirement Insurance TPA.
  • Across all categories, WNS was recognized for its deep domain expertise, innovative digital-first solutions , advanced analytics capabilities, and strategic platform partnerships.
  • “WNS’ ability to deliver digitally-led transformative offerings across insurance sectors while optimizing costs and enhancing efficiencies is well established.
  • “WNS is bolstering its position in the insurance BPO market by creating its proprietary offerings and forming new partnerships and alliances,” said Ashish Jhajharia, Lead Analyst, ISG.